{
    "body": "Is ocrelizumab effective for treatment of multiple sclerosis?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/27270678", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21341224", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24494635", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27116720", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22047971", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25887773", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26600872", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27718747", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24494619", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27552111", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27813441", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18951300", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24732658", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27389598", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25888198", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23609782", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22229582", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25887766", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26729332", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24928997", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20500147", 
        "http://www.ncbi.nlm.nih.gov/pubmed/27756172", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26702336", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22673950", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26788130", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25732947", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24507535"
    ], 
    "ideal_answer": [
        "Yes, ocrelizumab is effective for primary progressive form of multiple sclerosis."
    ], 
    "exact_answer": "yes", 
    "concepts": [
        "http://www.biosemantics.org/jochem#4002285", 
        "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009103", 
        "http://www.disease-ontology.org/api/metadata/DOID:2377"
    ], 
    "type": "yesno", 
    "id": "588fa4b9ed9bbee70d000006", 
    "snippets": [
        {
            "offsetInBeginSection": 672, 
            "offsetInEndSection": 995, 
            "text": " Advances made in immunomodulation are driving the progress being made in the treatment of MS. Ocrelizumab is the first treatment with positive results in the primarily progressive forms and tocilizumab, a drug product for rheumatoid arthritis, stands out as a potential candidate for the treatment of neuromyelitis optica.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27270678", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 682, 
            "offsetInEndSection": 903, 
            "text": " Expert commentary: The recent encouraging results of the ocrelizumab trial in PP MS, the first to reach the primary disability endpoint, indicate B cells as a promising therapeutic target to prevent disease progression. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27813441", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1038, 
            "offsetInEndSection": 1124, 
            "text": "Ocrelizumab also shows efficacy in the primary progressive form of multiple sclerosis.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27389598", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 72, 
            "text": "Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27552111", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 737, 
            "offsetInEndSection": 959, 
            "text": "Expert commentary: The topline results of two phase-III randomized clinical trials demonstrate superiority of ocrelizumab over interferon beta in RRMS patients with regards to clinical and paraclinical outcome parameters. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27552111", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 852, 
            "offsetInEndSection": 1109, 
            "text": "The efficacy of three of them, rituximab, ocrelizumab and ofatumumab in MS has been confirmed by placebo-controlled clinical trials demonstrating a significant reduction of the annualized relapsing rate (ARR), new gadolinium-enhancing (GdE) and T2 lesions. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27718747", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1133, 
            "offsetInEndSection": 1291, 
            "text": "Ongoing PMS trials are currently being conducted with the phosphodiesterase inhibitor ibudilast, S1P modulator siponimod and anti-B-cell therapy ocrelizumab. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25887766", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 213, 
            "offsetInEndSection": 407, 
            "text": "RECENT FINDINGS: Novel and imminently emerging DMTs for the treatment of RRMS include alemtuzumab, daclizumab, ocrelizumab, pegylated interferon-\u03b2-1a, and three times weekly glatiramer acetate. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25887773", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 369, 
            "text": "To summarize mechanisms of action, efficacy, and safety of novel and imminently emerging disease-modifying treatments (DMTs) intended to be used in relapsing-remitting multiple sclerosis (RRMS).Novel and imminently emerging DMTs for the treatment of RRMS include alemtuzumab, daclizumab, ocrelizumab, pegylated interferon-\u03b2-1a, and three times weekly glatiramer acetate", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25887773", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 116, 
            "text": "Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22047971", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 84, 
            "offsetInEndSection": 260, 
            "text": "We aimed to assess efficacy and safety of two dose regimens of the humanised anti-CD20 monoclonal antibody ocrelizumab in patients with relapsing-remitting multiple sclerosis. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22047971", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 166, 
            "text": "In multiple sclerosis (MS), B cell-depleting therapy using monoclonal anti-CD20 Abs, including rituximab (RTX) and ocrelizumab, effectively reduces disease activity. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24928997", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 998, 
            "offsetInEndSection": 1234, 
            "text": "Ocrelizumab also shows efficacy in the primary progressive form of multiple sclerosis.Most of the presented cell-depleting and myeloablative therapies are highly effective treatment options but are also accompanied by significant risks.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27389598", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 879, 
            "offsetInEndSection": 1288, 
            "text": "The armamentarium of approved disease-modifying therapies in MS and those in development include: (1) the first approved, moderately effective, injectable interferon-\u03b2 and glatiramer acetate; (2) oral drugs (fingolimod, laquinimod, teriflunomide, dimethyl fumarate); (3) monoclonal antibodies (rituximab, ocrelizumab, ofatumumab, daclizumab, alemtuzumab); and (4) immunosuppressive agents (e.g. mitoxantrone).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24732658", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 700, 
            "text": "BACKGROUND: B lymphocytes are implicated in the pathogenesis of multiple sclerosis. We aimed to assess efficacy and safety of two dose regimens of the humanised anti-CD20 monoclonal antibody ocrelizumab in patients with relapsing-remitting multiple sclerosis.METHODS: We did a multicentre, randomised, parallel, double-blind, placebo-controlled study involving 79 centres in 20 countries. Patients aged 18-55 years with relapsing-remitting multiple sclerosis were randomly assigned (1:1:1:1) via an interactive voice response system to receive either placebo, low-dose (600 mg) or high-dose (2000 mg) ocrelizumab in two doses on days 1 and 15, or intramuscular interferon beta-1a (30 \u00ecg) once a week.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22047971", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 73, 
            "text": "Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27552111", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 114, 
            "text": "The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26788130", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 117, 
            "text": "Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22047971", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 1001, 
            "offsetInEndSection": 1087, 
            "text": "Ocrelizumab also shows efficacy in the primary progressive form of multiple sclerosis.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/27389598", 
            "endSection": "abstract"
        }
    ]
}